Group 1 - The core viewpoint of the article highlights the performance and market presence of Green Leaf Pharmaceutical, which saw a stock price increase of 2.89% to 3.91 HKD per share with a trading volume of 302 million HKD on August 18 [1] - Green Leaf Pharmaceutical operates in four major therapeutic areas: oncology, central nervous system, cardiovascular, and digestive and metabolic diseases, focusing on the development, production, promotion, and sales of innovative drugs [1] - The company has a diverse product portfolio with over 30 products, and its sales network includes approximately 1,000 sales and marketing personnel and around 1,780 distributors, reaching over 19,330 hospitals in China and covering more than 80 countries and regions internationally [1] Group 2 - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1]
绿叶制药(02186)上涨2.89%，报3.91元/股